As pharma leverages real-world uses of AI, the industry has also been careful about big-picture hype for the technology as some of its limitations become clear.
Learn more.
Last summer, President Joe Biden declared victory over drugmakers in the war over the price of prescription medications: “We finally beat Big Pharma,” Biden said on the campaign trail with Vice President Kamala Harris during her bid for the presidency. His declaration came on the heels of Medicare’s first round of negotiation based on provisions within the Inflation Reduction Act.
Taking pharma companies to task over drug prices is a sure bet with the electorate, but government victories are often fleeting.
President Donald Trump’s current efforts to bring a “most favored nation” policy to life demonstrates the bipartisan call to arms. But access and affordability remain shrouded in a complex and opaque network, and Big Pharma’s control over drug launch prices is just one piece of the puzzle.
What role do drug launch prices play in the bigger picture of U.S. healthcare costs and what patients pay at the pharmacy counter? Today, we’re taking a look at an upcoming report from the Institute for Clinical and Economic Review, a U.S. drug pricing watchdog tracking the rising price of drugs at launch, and how it affects access and affordability down the line.
Thanks for reading.
Michael Gibney Senior Editor & Writer, PharmaVoice Email
The increased investment in cancer has brought a new era of treatments to the forefront including cell and gene therapies, antibody drug conjugates, checkpoint inhibitors and more. Learn more in this Trendline.
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
